3D細胞培養市場：タイプ（ハイドロゲル、ECM、ハンギングドロップ、バイオリアクター、マイクロ流体、磁気浮上）、アプリケーション（癌、幹細胞、毒性学、組織工学）、エンドユーザー（製薬、バイオテクノロジー、研究、化粧品）、地域別 - 2027年までの世界市場予測

3D Cell Culture Market by Type (Hydrogel, ECM, Hanging Drop, Bioreactor, Microfluidics, Magnetic Levitation), Application (Cancer, Stem Cell, Toxicology, Tissue Engineering), End User (Pharma, Biotech, Research, Cosmetics), Region - Global Forecast to 2027

3D細胞培養の世界市場は、2022年に13億米ドルと推定され、2027年には予測期間中に15.6%のCAGRで26億米ドルに達すると予測されています。この市場の成長は主に、動物実験に代わる方法の開発への注目の高まり、個別... もっと見る

出版社	出版年月	電子版価格	ページ数	図表数	言語
MarketsandMarkets マーケッツアンドマーケッツ	2022年5月25日	US$4,950 シングルユーザライセンスライセンス・価格情報注文方法はこちら	222	243	英語

日本語のページは自動翻訳を利用し作成しています。

サマリー

3D細胞培養の世界市場は、2022年に13億米ドルと推定され、2027年には予測期間中に15.6%のCAGRで26億米ドルに達すると予測されています。この市場の成長は主に、動物実験に代わる方法の開発への注目の高まり、個別化医療への注目の高まり、慢性疾患の発生率の増加、研究資金の確保などの要因によってもたらされます。一方、3D細胞を用いた研究のためのインフラの不足と細胞生物学研究の高コストが、予測期間中の同市場の成長を抑制すると予想されます。

"3D細胞培養市場において、予測期間中のタイプ別では足場ベースの3D細胞培養セグメントが最も高い成長率を占めている"
2021年、スキャフォールドベースの3D細胞培養セグメントが最も高い成長率を占めた。3D細胞培養における足場の利点である、構造的な剛性、取り付け位置の確保、サポートなどの利点が、足場ベースの3D細胞培養への好みを大きく後押しし、このセグメントの大きなシェアを確保しました。

"アジア太平洋地域。3D細胞培養市場の最速成長地域"
アジア太平洋地域は、予測期間中に最も高いCAGRを記録すると推定されます。これは、有利な規制ガイドラインの存在、細胞培養ベースのワクチン生産に対する政府の支援、低い製造コスト、アジアの新興国に対する世界の市場プレイヤーの焦点の高まりに起因するものである。

本レポートのために実施した主なインタビューは、以下のように分類できます。

- 回答者別供給側80％、需要側20
- 職位別Cレベル：45％、Dレベル：30％、その他：25
- 地域別地域別：北米20％、欧州10％、アジア太平洋55％、中南米10％、中近東・アフリカ5
報告書に掲載された企業一覧
- サーモフィッシャーサイエンティフィック（米国）
- メルクKGaA（ドイツ）
- コーニング・インコーポレイテッド（米国）
- ロンザグループAG（スイス）
- Avantor Inc.（米国）
- テカントレーディングAG（スイス）
- 3D Biotek LLC（米国）
- エミュレート・インク（米国）
- CNバイオ・イノベイションズ（英国）
- InSphero AG（スイス）
- グライナー・バイオワン・インターナショナルGmbH（オーストリア）
- 株式会社リプロセル（日本）
- カークストール社（英国）
- MIMETAS BV（オランダ）
- プロモセルGmbH（ドイツ）
- TissUse GmbH（ドイツ）
- Synthecon Incorporated（米国）
- QGel SA（スイス）
- レナバイオサイエンシズ（米国）
- Cellendes GmbH（ドイツ）
- アドバンストバイオマトリックス社（BICO社グループ）（米国）
- ビジコル社（米国）
- シンビボ社（米）
- UABフェレンティス社（リトアニア）
- ハミルトン社(米国)
調査対象範囲
本レポートは、世界の3D細胞培養市場の詳細図を提供します。タイプ、アプリケーション、エンドユーザー、地域などの異なるセグメントにおける市場規模および今後の成長可能性を推定することを目的としています。また、主要な市場プレイヤーの企業プロファイルや最近の開発状況、主要な市場戦略とともに、詳細な競合分析も掲載しています。

レポート購入の主なメリット
本レポートは、3D細胞培養市場全体とそのサブセグメントに関する収益数の最も近い概算を提供することで、市場リーダーや新規参入者を支援します。また、利害関係者が競争環境をより良く理解し、自社のビジネスをより良く位置づけ、適切な市場参入戦略を立てるためのより多くの洞察を得るのに役立ちます。本レポートは、利害関係者が市場の脈動を理解し、主要な市場ドライバー、課題、トレンド、機会に関する情報を提供することを可能にします。

ページTOPに戻る

1 INTRODUCTION 30
1.1 OBJECTIVES OF THE STUDY 30
1.2 MARKET DEFINITION 30
1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY 30
1.3 MARKET SCOPE 31
1.3.1 MARKETS COVERED 31
1.3.2 YEARS CONSIDERED FOR THE STUDY 31
1.4 CURRENCY 32
1.5 LIMITATIONS 32
1.6 STAKEHOLDERS 32
1.7 SUMMARY OF CHANGES 33
2 RESEARCH METHODOLOGY 34
2.1 RESEARCH DATA 34
FIGURE 1 RESEARCH DESIGN 34
2.1.1 SECONDARY DATA 35
2.1.2 PRIMARY DATA 36
FIGURE 2 BREAKDOWN OF PRIMARIES: 3D CELL CULTURE MARKET 36
2.2 MARKET ESTIMATION METHODOLOGY 37
FIGURE 3 3D CELL CULTURE MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2021 37
FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2021 37
2.2.1 INSIGHTS FROM PRIMARY EXPERTS 38
FIGURE 5 MARKET SIZE VALIDATION FROM PRIMARY SOURCES 38
2.3 MARKET GROWTH RATE PROJECTIONS 39
FIGURE 6 3D CELL CULTURE MARKET (SUPPLY-SIDE): CAGR PROJECTIONS 40
FIGURE 7 3D CELL CULTURE MARKET (DEMAND-SIDE): GROWTH ANALYSIS OF DEMAND-SIDE FACTORS 41
2.4 DATA TRIANGULATION 42
FIGURE 8 DATA TRIANGULATION METHODOLOGY 42
2.5 RESEARCH ASSUMPTIONS 43
2.5.1 COVID-19-SPECIFIC ASSUMPTIONS 43
2.6 RISK ANALYSIS 44
3 EXECUTIVE SUMMARY 45
FIGURE 9 3D CELL CULTURE MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION) 45
FIGURE 10 3D CELL CULTURE MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION) 46
FIGURE 11 3D CELL CULTURE MARKET, BY END USER, 2022 VS. 2027 (USD MILLION) 46
FIGURE 12 GEOGRAPHICAL SNAPSHOT OF THE 3D CELL CULTURE MARKET 47
4 PREMIUM INSIGHTS 48
4.1 3D CELL CULTURE MARKET OVERVIEW 48
FIGURE 13 INCREASING FOCUS ON DEVELOPING ALTERNATIVES TO ANIMAL TESTING IS A MAJOR FACTOR DRIVING THE ADOPTION OF 3D CELL CULTURE SOLUTIONS 48
4.2 NORTH AMERICA: 3D CELL CULTURE MARKET, BY TYPE AND COUNTRY (2021) 49
FIGURE 14 SCAFFOLD-BASED 3D CELL CULTURES ACCOUNTED FOR THE LARGEST SHARE OF THE NORTH AMERICAN 3D CELL CULTURE MARKET IN 2021 49
4.3 3D CELL CULTURE MARKET SHARE, BY APPLICATION, 2022 VS. 2027 50
FIGURE 15 CANCER & STEM CELL RESEARCH WILL CONTINUE TO DOMINATE THE MARKET IN 2027 50
4.4 3D CELL CULTURE MARKET SHARE, BY END USER, 2021 (USD MILLION) 50
FIGURE 16 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES DOMINATED THE MARKET IN 2021 50
4.5 3D CELL CULTURE MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 51
FIGURE 17 ASIA PACIFIC COUNTRIES TO REGISTER THE HIGHEST GROWTH RATE FROM 2022 TO 2027 51
5 MARKET OVERVIEW 52
5.1 INTRODUCTION 52
5.2 MARKET DYNAMICS 52
FIGURE 18 3D CELL CULTURE MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 52
5.2.1 DRIVERS 53
5.2.1.1 Increasing focus on developing alternatives to animal testing 53
5.2.1.2 Growing focus on personalized medicine 53
TABLE 1 GROWTH IN THE NUMBER OF PERSONALIZED MEDICINES 54
5.2.1.3 Increasing incidence of chronic diseases 54
TABLE 2 PREVALENCE OF DIABETES, BY REGION, 2000 VS. 2030 54
TABLE 3 INCIDENCE OF CANCER, BY TYPE, 2020 VS. 2040 55
5.2.1.4 Availability of funding for research 55
5.2.1.5 Growing demand for 3D cell culture 56
5.2.2 RESTRAINTS 56
5.2.2.1 Lack of infrastructure for 3D cell-based research 56
5.2.2.2 High cost of cell biology research 56
5.2.3 OPPORTUNITIES 57
5.2.3.1 Emergence of microfluidics-based 3D cell culture 57
5.2.3.2 Emerging economies 57
5.2.3.3 Regenerative medicine as an alternative to organ transplantation 57
5.2.3.4 Risk of pandemics and communicable diseases 58
5.2.4 CHALLENGES 58
5.2.4.1 Lack of consistency in 3D cell culture products 58
5.2.4.2 Plastic waste disposal 58
TABLE 4 COMPARISON OF SINGLE-USE BIOPROCESSING SYSTEM DISPOSAL OPTIONS 59
5.3 RANGES/SCENARIOS 60
FIGURE 19 SPECTRUM OF SCENARIOS BASED ON THE IMPACT OF UNCERTAINTIES ON THE GROWTH OF THE 3D CELL CULTURE MARKET 60
5.4 IMPACT OF THE COVID-19 OUTBREAK ON THE 3D CELL CULTURE MARKET 60
FIGURE 20 3D CELL CULTURE MARKET SCENARIO WITH AND WITHOUT COVID-19 IMPACT, 2020–2022 61
FIGURE 21 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 62
5.5 PRICING ANALYSIS 63
TABLE 5 SELLING PRICE OF 3D CELL CULTURE PRODUCTS BY TOP PLAYERS 63
5.6 TECHNOLOGY ANALYSIS 64
TABLE 6 ADVANTAGES AND DISADVANTAGES OF 3D CELL CULTURE TECHNIQUES 64
TABLE 7 ADVANTAGES AND DISADVANTAGES OF 3D CELL CULTURE METHODS 65
5.7 PATENT ANALYSIS 66
FIGURE 22 PATENT APPLICATIONS FOR THE CELL CULTURE MARKET,
JANUARY 2011–DECEMBER 2021 66
TABLE 8 INDICATIVE LIST OF PATENTS IN THE 3D CELL CULTURE MARKET 67
5.8 VALUE CHAIN ANALYSIS 68
FIGURE 23 VALUE CHAIN ANALYSIS OF THE 3D CELL CULTURE MARKET: RAW MATERIAL AND MANUFACTURING PHASE CONTRIBUTES MAXIMUM VALUE 68
5.9 SUPPLY CHAIN ANALYSIS 69
FIGURE 24 3D CELL CULTURE MARKET: SUPPLY CHAIN ANALYSIS 69
5.10 ECOSYSTEM ANALYSIS OF THE 3D CELL CULTURE MARKET 70
TABLE 9 SUPPLY CHAIN ECOSYSTEM 70
5.11 KEY CONFERENCES & EVENTS IN 2022–2023 72
TABLE 10 3D CELL CULTURE MARKET: DETAILED LIST OF CONFERENCES & EVENTS 72
5.12 REGULATORY ANALYSIS 74
5.12.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 74
TABLE 11 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 74
TABLE 12 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 74
TABLE 13 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 75
TABLE 14 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 75
5.13 PORTER’S FIVE FORCES ANALYSIS 76
TABLE 15 3D CELL CULTURE MARKET: PORTER’S FIVE FORCES ANALYSIS 76
5.13.1 THREAT OF NEW ENTRANTS 76
5.13.2 THREAT OF SUBSTITUTES 77
5.13.3 BARGAINING POWER OF SUPPLIERS 77
5.13.4 BARGAINING POWER OF BUYERS 77
5.13.5 COMPETITIVE RIVALRY AMONG EXISTING PLAYERS 77

5.14 KEY STAKEHOLDERS AND BUYING CRITERIA 78
5.14.1 KEY STAKEHOLDERS IN THE BUYING PROCESS 78
FIGURE 25 INFLUENCE OF STAKEHOLDERS IN THE BUYING PROCESS OF 3D CELL CULTURE PRODUCTS 78
5.14.2 BUYING CRITERIA FOR 3D CELL CULTURE PRODUCTS 78
FIGURE 26 KEY BUYING CRITERIA FOR END USERS 78
6 3D CELL CULTURE MARKET, BY TYPE 79
6.1 INTRODUCTION 80
TABLE 16 3D CELL CULTURE MARKET, BY TYPE, 2020–2027 (USD MILLION) 80
6.2 SCAFFOLD-BASED 3D CELL CULTURES 80
TABLE 17 SCAFFOLD-BASED 3D CELL CULTURES MARKET, BY TYPE,
2020–2027 (USD MILLION) 80
TABLE 18 SCAFFOLD-BASED 3D CELL CULTURES MARKET, BY REGION,
2020–2027 (USD MILLION) 81
TABLE 19 NORTH AMERICA: SCAFFOLD-BASED 3D CELL CULTURES MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 81
TABLE 20 EUROPE: SCAFFOLD-BASED 3D CELL CULTURES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 81
TABLE 21 ASIA PACIFIC: SCAFFOLD-BASED 3D CELL CULTURES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 82
6.2.1 HYDROGELS/ECM ANALOGS 82
6.2.1.1 Hydrogels/ECM analogs dominate the scaffold-based 3D cell cultures market 82
TABLE 22 HYDROGELS/ECM ANALOGS MARKET, BY REGION,
2020–2027 (USD MILLION) 82
TABLE 23 NORTH AMERICA: HYDROGELS/ECM ANALOGS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 83
TABLE 24 EUROPE: HYDROGELS/ECM ANALOGS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 83
TABLE 25 ASIA PACIFIC: HYDROGELS/ECM ANALOGS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 83
6.2.2 SOLID SCAFFOLDS 84
6.2.2.1 Solid scaffolds are widely adopted in regenerative medicine and preclinical in vitro testing 84
TABLE 26 SOLID SCAFFOLDS MARKET, BY REGION, 2020–2027 (USD MILLION) 84
TABLE 27 NORTH AMERICA: SOLID SCAFFOLDS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 85
TABLE 28 EUROPE: SOLID SCAFFOLDS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 85
TABLE 29 ASIA PACIFIC: SOLID SCAFFOLDS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 85
6.2.3 MICROPATTERNED SURFACES 86
6.2.3.1 Micropatterned surfaces enhance the expression of enzymes levels and drug reactivity 86
TABLE 30 MICROPATTERNED SURFACES MARKET, BY REGION,
2020–2027 (USD MILLION) 86
TABLE 31 NORTH AMERICA: MICROPATTERNED SURFACES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 86
TABLE 32 EUROPE: MICROPATTERNED SURFACES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 87
TABLE 33 ASIA PACIFIC: MICROPATTERNED SURFACES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 87
6.3 SCAFFOLD-FREE 3D CELL CULTURES 88
TABLE 34 SCAFFOLD-FREE 3D CELL CULTURES MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 88
TABLE 35 SCAFFOLD-FREE 3D CELL CULTURES MARKET, BY REGION,
2020–2027 (USD MILLION) 88
TABLE 36 NORTH AMERICA: SCAFFOLD-FREE 3D CELL CULTURES MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 88
TABLE 37 EUROPE: SCAFFOLD-FREE 3D CELL CULTURES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 89
TABLE 38 ASIA PACIFIC: SCAFFOLD-FREE 3D CELL CULTURES MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 89
6.3.1 LOW ATTACHMENT PLATES 89
6.3.1.1 Low attachment plates are expected to grow at the highest rate in the scaffold-free 3D cell cultures market 89
TABLE 39 LOW ATTACHMENT PLATES MARKET, BY REGION, 2020–2027 (USD MILLION) 90
TABLE 40 NORTH AMERICA: LOW ATTACHMENT PLATES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 90
TABLE 41 EUROPE: LOW ATTACHMENT PLATES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 90
TABLE 42 ASIA PACIFIC: LOW ATTACHMENT PLATES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 91
6.3.2 HANGING DROP PLATES 91
6.3.2.1 Hanging drop plates are widely used in stem cell differentiation and cytotoxicity research 91
TABLE 43 HANGING DROP PLATES MARKET, BY REGION, 2020–2027 (USD MILLION) 91
TABLE 44 NORTH AMERICA: HANGING DROP PLATES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 92
TABLE 45 EUROPE: HANGING DROP PLATES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 92
TABLE 46 ASIA PACIFIC: HANGING DROP PLATES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 92
6.3.3 3D BIOREACTORS 93
6.3.3.1 3D bioreactors are commonly used in the mass production of cells 93
TABLE 47 3D BIOREACTORS MARKET, BY REGION, 2020–2027 (USD MILLION) 93
TABLE 48 NORTH AMERICA: 3D BIOREACTORS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 93
TABLE 49 EUROPE: 3D BIOREACTORS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 94
TABLE 50 ASIA PACIFIC: 3D BIOREACTORS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 94
6.3.4 3D PETRI DISHES 94
6.3.4.1 Europe will witness the highest growth in the 3D Petri dishes market 94
TABLE 51 3D PETRI DISHES MARKET, BY REGION, 2020–2027 (USD MILLION) 95
TABLE 52 NORTH AMERICA: 3D PETRI DISHES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 95
TABLE 53 EUROPE: 3D PETRI DISHES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 95
TABLE 54 ASIA PACIFIC: 3D PETRI DISHES MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 96
6.4 MICROFLUIDICS-BASED 3D CELL CULTURES 96
6.4.1 MICROFLUIDICS-BASED 3D CELL CULTURES WILL GROW AT THE HIGHEST RATE IN THE 3D CELL CULTURE MARKET 96
TABLE 55 MICROFLUIDICS-BASED 3D CELL CULTURE MARKET, BY REGION,
2020–2027 (USD MILLION) 97
TABLE 56 NORTH AMERICA: MICROFLUIDICS-BASED 3D CELL CULTURE MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 97
TABLE 57 EUROPE: MICROFLUIDICS-BASED 3D CELL CULTURE MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 97
TABLE 58 ASIA PACIFIC: MICROFLUIDICS-BASED 3D CELL CULTURE MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 98
6.5 MAGNETIC & BIOPRINTED 3D CELL CULTURES 98
6.5.1 3D CELL CULTURE CAN BE FORMED WITHOUT MEDIA IN MAGNETIC LEVITATION 98
TABLE 59 MAGNETIC & BIOPRINTED 3D CELL CULTURES MARKET, BY REGION,
2020–2027 (USD MILLION) 98
TABLE 60 NORTH AMERICA: MAGNETIC & BIOPRINTED 3D CELL CULTURES MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 99
TABLE 61 EUROPE: MAGNETIC & BIOPRINTED 3D CELL CULTURES MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 99
TABLE 62 ASIA PACIFIC: MAGNETIC & BIOPRINTED 3D CELL CULTURES MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 99
7 3D CELL CULTURE MARKET, BY APPLICATION 100
7.1 INTRODUCTION 101
TABLE 63 3D CELL CULTURE MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 101
7.2 CANCER & STEM CELL RESEARCH 101
7.2.1 RISING PREVALENCE OF CANCER IS A KEY FACTOR DRIVING THE GROWTH OF THIS SEGMENT 101
TABLE 64 3D CELL CULTURE MARKET FOR CANCER & STEM CELL RESEARCH,
BY REGION, 2020–2027 (USD MILLION) 102
TABLE 65 NORTH AMERICA: 3D CELL CULTURE MARKET FOR CANCER & STEM CELL RESEARCH, BY COUNTRY, 2020–2027 (USD MILLION) 102
TABLE 66 EUROPE: 3D CELL CULTURE MARKET FOR CANCER & STEM CELL RESEARCH, BY COUNTRY, 2020–2027 (USD MILLION) 103
TABLE 67 ASIA PACIFIC: 3D CELL CULTURE MARKET FOR CANCER & STEM CELL RESEARCH, BY COUNTRY, 2020–2027 (USD MILLION) 103
7.3 DRUG DISCOVERY & TOXICOLOGY TESTING 103
7.3.1 INCREASING ADOPTION OF PERSONALIZED MEDICINES TO SUPPORT MARKET GROWTH 103
TABLE 68 3D CELL CULTURE MARKET FOR DRUG DISCOVERY & TOXICOLOGY TESTING, BY REGION, 2020–2027 (USD MILLION) 104
TABLE 69 NORTH AMERICA: 3D CELL CULTURE MARKET FOR DRUG DISCOVERY & TOXICOLOGY TESTING, BY COUNTRY, 2020–2027 (USD MILLION) 104
TABLE 70 EUROPE: 3D CELL CULTURE MARKET FOR DRUG DISCOVERY & TOXICOLOGY TESTING, BY COUNTRY, 2020–2027 (USD MILLION) 105
TABLE 71 ASIA PACIFIC: 3D CELL CULTURE MARKET FOR DRUG DISCOVERY & TOXICOLOGY TESTING, BY COUNTRY, 2020–2027 (USD MILLION) 105
7.4 TISSUE ENGINEERING & REGENERATIVE MEDICINE 105
7.4.1 INCREASING TISSUE ENGINEERING & REGENERATIVE MEDICINE RESEARCH TO DRIVE THIS MARKET 105
TABLE 72 3D CELL CULTURE MARKET FOR TISSUE ENGINEERING & REGENERATIVE MEDICINE, BY REGION, 2020–2027 (USD MILLION) 106
TABLE 73 NORTH AMERICA: 3D CELL CULTURE MARKET FOR TISSUE ENGINEERING & REGENERATIVE MEDICINE, BY COUNTRY, 2020–2027 (USD MILLION) 106
TABLE 74 EUROPE: 3D CELL CULTURE MARKET FOR TISSUE ENGINEERING & REGENERATIVE MEDICINE, BY COUNTRY, 2020–2027 (USD MILLION) 107
TABLE 75 ASIA PACIFIC: 3D CELL CULTURE MARKET FOR TISSUE ENGINEERING & REGENERATIVE MEDICINE, BY COUNTRY, 2020–2027 (USD MILLION) 107
8 3D CELL CULTURE MARKET, BY END USER 108
8.1 INTRODUCTION 109
TABLE 76 3D CELL CULTURE MARKET, BY END USER, 2020–2027 (USD MILLION) 109
8.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 109
8.2.1 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES ARE THE LARGEST END USERS OF 3D CELL CULTURE PRODUCTS 109
TABLE 77 3D CELL CULTURE MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2020–2027 (USD MILLION) 110
TABLE 78 NORTH AMERICA: 3D CELL CULTURE MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 110
TABLE 79 EUROPE: 3D CELL CULTURE MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 110
TABLE 80 ASIA PACIFIC: 3D CELL CULTURE MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 111
8.3 RESEARCH INSTITUTES 111
8.3.1 INCREASING GOVERNMENT FUNDING FOR RESEARCH & HIGH PREVALENCE OF CANCER ARE DRIVING MARKET GROWTH 111
TABLE 81 3D CELL CULTURE MARKET FOR RESEARCH INSTITUTES, BY REGION,
2020–2027 (USD MILLION) 112
TABLE 82 NORTH AMERICA: 3D CELL CULTURE MARKET FOR RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION) 112
TABLE 83 EUROPE: 3D CELL CULTURE MARKET FOR RESEARCH INSTITUTES,
BY COUNTRY, 2020–2027 (USD MILLION) 112
TABLE 84 ASIA PACIFIC: 3D CELL CULTURE MARKET FOR RESEARCH INSTITUTES,
BY COUNTRY, 2020–2027 (USD MILLION) 113
8.4 COSMETICS INDUSTRY 113
8.4.1 FOCUS ON DEVELOPING ALTERNATIVES TO ANIMAL TESTING IS A KEY FACTOR DRIVING MARKET GROWTH 113
TABLE 85 3D CELL CULTURE MARKET FOR THE COSMETICS INDUSTRY, BY REGION, 2020–2027 (USD MILLION) 113
TABLE 86 NORTH AMERICA: 3D CELL CULTURE MARKET FOR THE COSMETICS INDUSTRY, BY COUNTRY, 2020–2027 (USD MILLION) 114
TABLE 87 EUROPE: 3D CELL CULTURE MARKET FOR THE COSMETICS INDUSTRY,
BY COUNTRY, 2020–2027 (USD MILLION) 114
TABLE 88 ASIA PACIFIC: 3D CELL CULTURE MARKET FOR THE COSMETICS INDUSTRY, BY COUNTRY, 2020–2027 (USD MILLION) 114
8.5 OTHER END USERS 115
TABLE 89 3D CELL CULTURE MARKET FOR OTHER END USERS, BY REGION,
2020–2027 (USD MILLION) 115
TABLE 90 NORTH AMERICA: 3D CELL CULTURE MARKET FOR OTHER END USERS,
BY COUNTRY, 2020–2027 (USD MILLION) 115
TABLE 91 EUROPE: 3D CELL CULTURE MARKET FOR OTHER END USERS, BY COUNTRY, 2020–2027 (USD MILLION) 116
TABLE 92 ASIA PACIFIC: 3D CELL CULTURE MARKET FOR OTHER END USERS,
BY COUNTRY, 2020–2027 (USD MILLION) 116
9 3D CELL CULTURE MARKET, BY REGION 117
9.1 INTRODUCTION 118
TABLE 93 3D CELL CULTURE MARKET, BY REGION, 2020–2027 (USD MILLION) 118
9.2 NORTH AMERICA 119
FIGURE 27 NORTH AMERICA: 3D CELL CULTURE MARKET SNAPSHOT 119
TABLE 94 NORTH AMERICA: 3D CELL CULTURE MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 120
TABLE 95 NORTH AMERICA: 3D CELL CULTURE MARKET, BY TYPE,
2020–2027 (USD MILLION) 120
TABLE 96 NORTH AMERICA: SCAFFOLD-BASED 3D CELL CULTURES MARKET, BY TYPE, 2020–2027 (USD MILLION) 120
TABLE 97 NORTH AMERICA: SCAFFOLD-FREE 3D CELL CULTURES MARKET, BY TYPE, 2020–2027 (USD MILLION) 121
TABLE 98 NORTH AMERICA: 3D CELL CULTURE MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 121
TABLE 99 NORTH AMERICA: 3D CELL CULTURE MARKET, BY END USER,
2020–2027 (USD MILLION) 121
9.2.1 US 122
9.2.1.1 The US dominates the North American market 122
TABLE 100 US: 3D CELL CULTURE MARKET, BY TYPE, 2020–2027 (USD MILLION) 122
TABLE 101 US: SCAFFOLD-BASED 3D CELL CULTURES MARKET, BY TYPE,
2020–2027 (USD MILLION) 123
TABLE 102 US: SCAFFOLD-FREE 3D CELL CULTURES MARKET, BY TYPE,
2020–2027 (USD MILLION) 123
TABLE 103 US: 3D CELL CULTURE MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 123
TABLE 104 US: 3D CELL CULTURE MARKET, BY END USER, 2020–2027 (USD MILLION) 124
9.2.2 CANADA 124
9.2.2.1 Advancements in regenerative medicine to drive market growth in Canada 124
TABLE 105 CANADA: 3D CELL CULTURE MARKET, BY TYPE, 2020–2027 (USD MILLION) 125
TABLE 106 CANADA: SCAFFOLD-BASED 3D CELL CULTURES MARKET, BY TYPE,
2020–2027 (USD MILLION) 125
TABLE 107 CANADA: SCAFFOLD-FREE 3D CELL CULTURES MARKET, BY TYPE,
2020–2027 (USD MILLION) 125
TABLE 108 CANADA: 3D CELL CULTURE MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 126
TABLE 109 CANADA: 3D CELL CULTURE MARKET, BY END USER,
2020–2027 (USD MILLION) 126
9.3 EUROPE 127
TABLE 110 EUROPE: 3D CELL CULTURE MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 128
TABLE 111 EUROPE: 3D CELL CULTURE MARKET, BY TYPE, 2020–2027 (USD MILLION) 128
TABLE 112 EUROPE: SCAFFOLD-BASED 3D CELL CULTURES MARKET, BY TYPE,
2020–2027 (USD MILLION) 128
TABLE 113 EUROPE: SCAFFOLD-FREE 3D CELL CULTURES MARKET, BY TYPE,
2020–2027 (USD MILLION) 129
TABLE 114 EUROPE: 3D CELL CULTURE MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 129
TABLE 115 EUROPE: 3D CELL CULTURE MARKET, BY END USER,
2020–2027 (USD MILLION) 129
9.3.1 GERMANY 130
9.3.1.1 Germany dominates the 3D cell culture market in Europe 130
TABLE 116 GERMANY: 3D CELL CULTURE MARKET, BY TYPE, 2020–2027 (USD MILLION) 130
TABLE 117 GERMANY: SCAFFOLD-BASED 3D CELL CULTURES MARKET, BY TYPE,
2020–2027 (USD MILLION) 131
TABLE 118 GERMANY: SCAFFOLD-FREE 3D CELL CULTURES MARKET, BY TYPE,
2020–2027 (USD MILLION) 131
TABLE 119 GERMANY: 3D CELL CULTURE MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 131
TABLE 120 GERMANY: 3D CELL CULTURE MARKET, BY END USER,
2020–2027 (USD MILLION) 132
9.3.2 UK 132
9.3.2.1 Growth in the life sciences industry to drive market growth in the UK 132
TABLE 121 UK: 3D CELL CULTURE MARKET, BY TYPE, 2020–2027 (USD MILLION) 133
TABLE 122 UK: SCAFFOLD-BASED 3D CELL CULTURES MARKET, BY TYPE,
2020–2027 (USD MILLION) 133
TABLE 123 UK: SCAFFOLD-FREE 3D CELL CULTURES MARKET, BY TYPE,
2020–2027 (USD MILLION) 133
TABLE 124 UK: 3D CELL CULTURE MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 134
TABLE 125 UK: 3D CELL CULTURE MARKET, BY END USER, 2020–2027 (USD MILLION) 134
9.3.3 FRANCE 134
9.3.3.1 Biotech industry growth supports the market in France 134
TABLE 126 FRANCE: 3D CELL CULTURE MARKET, BY TYPE, 2020–2027 (USD MILLION) 135
TABLE 127 FRANCE: SCAFFOLD-BASED 3D CELL CULTURES MARKET, BY TYPE,
2020–2027 (USD MILLION) 135
TABLE 128 FRANCE: SCAFFOLD-FREE 3D CELL CULTURES MARKET, BY TYPE,
2020–2027 (USD MILLION) 135
TABLE 129 FRANCE: 3D CELL CULTURE MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 136
TABLE 130 FRANCE: 3D CELL CULTURE MARKET, BY END USER,
2020–2027 (USD MILLION) 136
9.3.4 ITALY 136
9.3.4.1 Italy is a leading life science research hub in Europe 136
TABLE 131 ITALY: 3D CELL CULTURE MARKET, BY TYPE, 2020–2027 (USD MILLION) 137
TABLE 132 ITALY: SCAFFOLD-BASED 3D CELL CULTURES MARKET, BY TYPE,
2020–2027 (USD MILLION) 138
TABLE 133 ITALY: SCAFFOLD-FREE 3D CELL CULTURES MARKET, BY TYPE,
2020–2027 (USD MILLION) 138
TABLE 134 ITALY: 3D CELL CULTURE MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 138
TABLE 135 ITALY: 3D CELL CULTURE MARKET, BY END USER,
2020–2027 (USD MILLION) 139
9.3.5 SPAIN 139
9.3.5.1 Increasing funding from private and public organizations to aid market growth in Spain 139
TABLE 136 SPAIN: 3D CELL CULTURE MARKET, BY TYPE, 2020–2027 (USD MILLION) 140
TABLE 137 SPAIN: SCAFFOLD-BASED 3D CELL CULTURES MARKET, BY TYPE,
2020–2027 (USD MILLION) 140
TABLE 138 SPAIN: SCAFFOLD-FREE 3D CELL CULTURES MARKET, BY TYPE,
2020–2027 (USD MILLION) 140
TABLE 139 SPAIN: 3D CELL CULTURE MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 141
TABLE 140 SPAIN: 3D CELL CULTURE MARKET, BY END USER,
2020–2027 (USD MILLION) 141
9.3.6 ROE 141
TABLE 141 ROE: 3D CELL CULTURE MARKET, BY TYPE, 2020–2027 (USD MILLION) 141
TABLE 142 ROE: SCAFFOLD-BASED 3D CELL CULTURES MARKET, BY TYPE,
2020–2027 (USD MILLION) 142
TABLE 143 ROE: SCAFFOLD-FREE 3D CELL CULTURES MARKET, BY TYPE,
2020–2027 (USD MILLION) 142
TABLE 144 ROE: 3D CELL CULTURE MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 142
TABLE 145 ROE: 3D CELL CULTURE MARKET, BY END USER, 2020–2027 (USD MILLION) 143
9.4 ASIA PACIFIC 144
FIGURE 28 ASIA PACIFIC: 3D CELL CULTURE MARKET SNAPSHOT 144
TABLE 146 APAC: 3D CELL CULTURE MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 145
TABLE 147 APAC: 3D CELL CULTURE MARKET, BY TYPE, 2020–2027 (USD MILLION) 145
TABLE 148 APAC: SCAFFOLD-BASED 3D CELL CULTURES MARKET, BY TYPE,
2020–2027 (USD MILLION) 145
TABLE 149 APAC: SCAFFOLD-FREE 3D CELL CULTURES MARKET, BY TYPE,
2020–2027 (USD MILLION) 146
TABLE 150 APAC: 3D CELL CULTURE MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 146
TABLE 151 APAC: 3D CELL CULTURE MARKET, BY END USER,
2020–2027 (USD MILLION) 146
9.4.1 CHINA 147
9.4.1.1 Government support & strategic initiatives by key players to strengthen the biotechnology sector in China 147
TABLE 152 CHINA: 3D CELL CULTURE MARKET, BY TYPE, 2020–2027 (USD MILLION) 147
TABLE 153 CHINA: SCAFFOLD-BASED 3D CELL CULTURES MARKET, BY TYPE,
2020–2027 (USD MILLION) 148
TABLE 154 CHINA: SCAFFOLD-FREE 3D CELL CULTURES MARKET, BY TYPE,
2020–2027 (USD MILLION) 148
TABLE 155 CHINA: 3D CELL CULTURE MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 148
TABLE 156 CHINA: 3D CELL CULTURE MARKET, BY END USER,
2020–2027 (USD MILLION) 149
9.4.2 JAPAN 149
9.4.2.1 Rising cancer rate, growing geriatric population, and subsequent rise in healthcare spending to drive the market growth 149
TABLE 157 JAPAN: 3D CELL CULTURE MARKET, BY TYPE, 2020–2027 (USD MILLION) 150
TABLE 158 JAPAN: SCAFFOLD-BASED 3D CELL CULTURES MARKET, BY TYPE,
2020–2027 (USD MILLION) 150
TABLE 159 JAPAN: SCAFFOLD-FREE 3D CELL CULTURES MARKET, BY TYPE,
2020–2027 (USD MILLION) 150
TABLE 160 JAPAN: 3D CELL CULTURE MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 151
TABLE 161 JAPAN: 3D CELL CULTURE MARKET, BY END USER,
2020–2027 (USD MILLION) 151
9.4.3 INDIA 151
9.4.3.1 Growth in the life sciences industry to support market growth in India 151
TABLE 162 INDIA: 3D CELL CULTURE MARKET, BY TYPE, 2020–2027 (USD MILLION) 152
TABLE 163 INDIA: SCAFFOLD-BASED 3D CELL CULTURES MARKET, BY TYPE,
2020–2027 (USD MILLION) 152
TABLE 164 INDIA: SCAFFOLD-FREE 3D CELL CULTURES MARKET, BY TYPE,
2020–2027 (USD MILLION) 153
TABLE 165 INDIA: 3D CELL CULTURE MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 153
TABLE 166 INDIA: 3D CELL CULTURE MARKET, BY END USER,
2020–2027 (USD MILLION) 153
9.4.4 ROAPAC 154
TABLE 167 ROAPAC: 3D CELL CULTURE MARKET, BY TYPE, 2020–2027 (USD MILLION) 154
TABLE 168 ROAPAC: SCAFFOLD-BASED 3D CELL CULTURES MARKET, BY TYPE,
2020–2027 (USD MILLION) 155
TABLE 169 ROAPAC: SCAFFOLD-FREE 3D CELL CULTURES MARKET, BY TYPE,
2020–2027 (USD MILLION) 155
TABLE 170 ROAPAC: 3D CELL CULTURE MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 155
TABLE 171 ROAPAC: 3D CELL CULTURE MARKET, BY END USER,
2020–2027 (USD MILLION). 156
9.5 LATIN AMERICA 156
9.5.1 RISING CANCER RATE AND GROWING SUPPORT FOR RESEARCH TO DRIVE MARKET GROWTH 156
TABLE 172 LATIN AMERICA: 3D CELL CULTURE MARKET, BY TYPE,
2020–2027 (USD MILLION) 157
TABLE 173 LATIN AMERICA: SCAFFOLD-BASED 3D CELL CULTURES MARKET, BY TYPE, 2020–2027 (USD MILLION) 157
TABLE 174 LATIN AMERICA: SCAFFOLD-FREE 3D CELL CULTURES MARKET, BY TYPE, 2020–2027 (USD MILLION) 157
TABLE 175 LATIN AMERICA: 3D CELL CULTURE MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 158
TABLE 176 LATIN AMERICA: 3D CELL CULTURE MARKET, BY END USER,
2020–2027 (USD MILLION) 158
9.6 MIDDLE EAST & AFRICA 159
9.6.1 INCREASING FUNDING AND PARTNERSHIPS IN RESEARCH TO SUPPORT MARKET GROWTH 159
TABLE 177 MIDDLE EAST & AFRICA: 3D CELL CULTURE MARKET, BY TYPE,
2020–2027 (USD MILLION) 159
TABLE 178 MIDDLE EAST & AFRICA: SCAFFOLD-BASED 3D CELL CULTURES MARKET,
BY TYPE, 2020–2027 (USD MILLION) 160
TABLE 179 MIDDLE EAST & AFRICA: SCAFFOLD-FREE 3D CELL CULTURES MARKET,
BY TYPE, 2020–2027 (USD MILLION) 160
TABLE 180 MIDDLE EAST & AFRICA: 3D CELL CULTURE MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 160
TABLE 181 MIDDLE EAST & AFRICA: 3D CELL CULTURE MARKET, BY END USER,
2020–2027 (USD MILLION) 161
10 COMPETITIVE LANDSCAPE 162
10.1 OVERVIEW 162
10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 163
FIGURE 29 KEY DEVELOPMENTS IN THE 3D CELL CULTURE MARKET, 2019–2022 163
10.3 MARKET SHARE ANALYSIS 164
FIGURE 30 3D CELL CULTURE MARKET: MARKET SHARE ANALYSIS, BY KEY PLAYER, 2021 164
TABLE 182 3D CELL CULTURE MARKET: DEGREE OF COMPETITION 164
10.4 REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS 166
FIGURE 31 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN THE 3D CELL CULTURE MARKET, 2019–2021 166
10.5 COMPANY EVALUATION QUADRANT 167
10.5.1 STARS 167
10.5.2 EMERGING LEADERS 167
10.5.3 PERVASIVE PLAYERS 167
10.5.4 PARTICIPANTS 167
FIGURE 32 3D CELL CULTURE MARKET: COMPANY EVALUATION QUADRANT, 2021 168
10.6 COMPANY EVALUATION QUADRANT: START-UPS/SMES 169
10.6.1 PROGRESSIVE COMPANIES 169
10.6.2 STARTING BLOCKS 169
10.6.3 RESPONSIVE COMPANIES 169
10.6.4 DYNAMIC COMPANIES 169
FIGURE 33 3D CELL CULTURE MARKET: COMPANY EVALUATION QUADRANT FOR START-UPS/SMES, 2021 170
10.7 COMPANY FOOTPRINT ANALYSIS 171
10.7.1 COMPANY PRODUCT FOOTPRINT 171
TABLE 183 COMPANY PRODUCT FOOTPRINT: 3D CELL CULTURE MARKET (2021) 171
10.7.2 COMPANY REGIONAL FOOTPRINT 172
TABLE 184 COMPANY REGIONAL FOOTPRINT: 3D CELL CULTURE MARKET (2021) 172
10.7.3 COMPETITIVE BENCHMARKING OF STARTUP/SME PLAYERS 173
TABLE 185 3D CELL CULTURE MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS 173
TABLE 186 3D CELL CULTURE MARKET: COMPETITIVE BENCHMARKING OF STARTUP/SME PLAYERS 175
10.8 COMPETITIVE SCENARIO 176
TABLE 187 PRODUCT LAUNCHES 176
TABLE 188 DEALS 177
TABLE 189 OTHER DEVELOPMENTS 177
11 COMPANY PROFILES 178
11.1 KEY PLAYERS 178
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
11.1.1 THERMO FISHER SCIENTIFIC, INC. 178
TABLE 190 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW 178
FIGURE 34 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2020) 179
11.1.2 MERCK KGAA 183
TABLE 191 MERCK KGAA: BUSINESS OVERVIEW 183
FIGURE 35 MERCK KGAA: COMPANY SNAPSHOT (2021) 184
11.1.3 CORNING INCORPORATED 187
TABLE 192 CORNING INCORPORATED: BUSINESS OVERVIEW 187
FIGURE 36 CORNING INCORPORATED: COMPANY SNAPSHOT (2021) 188
11.1.4 LONZA GROUP AG 191
TABLE 193 LONZA GROUP AG: BUSINESS OVERVIEW 191
FIGURE 37 LONZA GROUP AG: COMPANY SNAPSHOT (2020) 192
11.1.5 TECAN TRADING AG 194
TABLE 194 TECAN TRADING AG: BUSINESS OVERVIEW 194
FIGURE 38 TECAN TRADING AG: COMPANY SNAPSHOT (2021) 195
11.1.6 AVANTOR, INC. 196
TABLE 195 AVANTOR, INC.: BUSINESS OVERVIEW 196
FIGURE 39 AVANTOR, INC: COMPANY SNAPSHOT (2021) 196
11.1.7 REPROCELL INC. 198
TABLE 196 REPROCELL: BUSINESS OVERVIEW 198
11.1.8 3D BIOTEK LLC 201
TABLE 197 3D BIOTEK LLC: BUSINESS OVERVIEW 201
11.1.9 EMULATE, INC. 202
TABLE 198 EMULATE, INC.: BUSINESS OVERVIEW 202
11.1.10 CN BIO INNOVATIONS LIMITED 204
TABLE 199 CN BIO INNOVATIONS LIMITED: BUSINESS OVERVIEW 204
11.1.11 SYNTHECON, INCORPORATED 207
TABLE 200 SYNTHECON, INCORPORATED: BUSINESS OVERVIEW 207
11.1.12 INSPHERO AG 209
TABLE 201 INSPHERO AG: BUSINESS OVERVIEW 209
11.1.13 KIRKSTALL LTD. 212
TABLE 202 KIRKSTALL LTD.: BUSINESS OVERVIEW 212
11.1.14 MIMETAS BV 213
TABLE 203 MIMETAS BV: BUSINESS OVERVIEW 213
11.1.15 TISSUSE GMBH 216
TABLE 204 TISSUSE GMBH: BUSINESS OVERVIEW 216
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
11.2 OTHER PLAYERS 218
11.2.1 HAMILTON COMPANY 218
11.2.2 QGEL SA 218
11.2.3 LENA BIOSCIENCES 219
11.2.4 CELLENDES GMBH 219
11.2.5 UAB FERENTIS 220
11.2.6 GREINER BIO-ONE INTERNATIONAL GMBH 220
11.2.7 PROMOCELL GMBH 221
11.2.8 ADVANCED BIOMATRIX, INC. (PART OF BICO GROUP) 221
11.2.9 VISIKOL, INC. (FORMERLY HUREL CORPORATION) 222
11.2.10 SYNVIVO INC. 223
12 APPENDIX 224
12.1 DISCUSSION GUIDE 224
12.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 227
12.3 AVAILABLE CUSTOMIZATIONS 229
12.4 RELATED REPORTS 229
12.5 AUTHOR DETAILS 230

ページTOPに戻る

Table of Contents

Summary

The global 3D cell culture market is valued at an estimated USD 1.3 billion in 2022 and is projected to reach USD 2.6 billion by 2027, at a CAGR of 15.6% during the forecast period. The growth of this market is mainly driven by factors such as the increasing focus on developing alternative methods to animal testing, growing focus on personalized medicine, increasing incidence of chronic diseases, and the availability of funding for research. On the other hand, a lack of infrastructure for 3D cell-based research and the high cost of cell biology research are expected to restrain the growth of this market during the forecast period.

“The scaffold-based 3D cell culture segment accounted for the highest growth rate in the 3D Cell culture market, by type, during the forecast period”
In 2021, the scaffold-based 3D cell culture segment accounted for the highest growth rate. The advantages of scaffolds in 3D cell culture, such as structural rigidity, the availability of attachment points, and support, have greatly driven the preference for scaffold-based 3D cell cultures and ensured the large share of this segment.

“Asia Pacific: The fastest-growing region in the 3D Cell culture market”
The Asia Pacific market is estimated to record the highest CAGR during the forecast period. This is attributed to the presence of favorable regulatory guidelines, government support for cell culture-based vaccine production, low manufacturing costs, and the growing focus of global market players on emerging Asian countries.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side- 80% and Demand Side 20%
• By Designation: C-level - 45%, D-level - 30%, and Others - 25%
• By Region: North America -20%, Europe -10%, Asia-Pacific -55%, Latin America -10%, Middle East & Africa- 5%
List of Companies Profiled in the Report:
• Thermo Fisher Scientific (US)
• Merck KGaA (Germany)
• Corning Incorporated (US)
• Lonza Group AG (Switzerland)
• Avantor Inc. (US)
• Tecan Trading AG (Switzerland)
• 3D Biotek LLC (US)
• Emulate Inc. (US)
• CN Bio Innovations (UK)
• InSphero AG (Switzerland)
• Greiner Bio-One International GmbH (Austria)
• REPROCELL Inc. (Japan)
• Kirkstall Ltd (UK)
• MIMETAS BV (Netherlands)
• PromoCell GmbH (Germany)
• TissUse GmbH (Germany)
• Synthecon Incorporated (US)
• QGel SA (Switzerland)
• Lena Biosciences (US)
• Cellendes GmbH (Germany)
• Advanced BioMatrix Inc. (Part of BICO Group) (US)
• Visikol Inc. (US)
• SynVivo Inc. (US)
• UAB Ferentis (Lithuania)
• Hamilton Company(US)
Research Coverage:
This report provides a detailed picture of the global 3D Cell culture Market. It aims at estimating the size and future growth potential of the market across different segments such as the type, application, end user and region. The report also includes an in-depth competitive analysis of the key market players along with their company profiles recent developments and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall 3D Cell culture Market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, challenges, trends, and opportunities.

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（バイオ薬物）の最新刊レポート

MarketsandMarkets社のバイオ薬物分野での最新刊レポート

本レポートと同じKEY WORD（hydrogel）の最新刊レポート

本レポートと同じKEY WORDの最新刊レポートはありません。

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

マーケッツアンドマーケッツ（MarketsandMarkets）は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野（バイオ薬物）の最新刊レポート

MarketsandMarkets社のバイオ薬物分野での最新刊レポート

本レポートと同じKEY WORD（hydrogel）の最新刊レポート

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?